Medication	O
Intervention	O
for	O
Chronic	B:C1561643
Kidney	I:C1561643
Disease	I:C1561643
Patients	O
Transitioning	O
from	O
Hospital	O
to	O
Home	O
:	O
Study	O
Design	I:C0035171
and	O
Baseline	O
Characteristics	O
.	O

Medication	O
Intervention	O
for	O
Chronic	O
Kidney	I:C1561643
Disease	I:C1561643
Patients	O
Transitioning	O
from	O
Hospital	B:C0019994
to	O
Home	O
:	O
Study	O
Design	I:C0035171
and	O
Baseline	O
Characteristics	O
.	O

Medication	O
Intervention	O
for	O
Chronic	O
Kidney	I:C1561643
Disease	I:C1561643
Patients	O
Transitioning	O
from	O
Hospital	O
to	O
Home	B:C0442519
:	O
Study	O
Design	I:C0035171
and	O
Baseline	O
Characteristics	O
.	O

Medication	O
Intervention	O
for	O
Chronic	O
Kidney	I:C1561643
Disease	I:C1561643
Patients	O
Transitioning	O
from	O
Hospital	O
to	O
Home	O
:	O
Study	B:C0035171
Design	I:C0035171
and	O
Baseline	O
Characteristics	O
.	O

The	O
hospital	B:C0600290
readmission	I:C0600290
rate	O
in	O
the	O
population	O
with	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
(	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
)	O
is	O
high	O
and	O
strategies	O
to	O
reduce	O
this	O
risk	O
are	O
urgently	O
needed	O
.	O

The	O
hospital	O
readmission	I:C0600290
rate	O
in	O
the	O
population	B:C1257890
with	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
(	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
)	O
is	O
high	O
and	O
strategies	O
to	O
reduce	O
this	O
risk	O
are	O
urgently	O
needed	O
.	O

The	O
hospital	O
readmission	I:C0600290
rate	O
in	O
the	O
population	O
with	O
chronic	B:C1561643
kidney	I:C1561643
disease	I:C1561643
(	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
)	O
is	O
high	O
and	O
strategies	O
to	O
reduce	O
this	O
risk	O
are	O
urgently	O
needed	O
.	O

The	O
hospital	O
readmission	I:C0600290
rate	O
in	O
the	O
population	O
with	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
(	O
chronic	B:C1561643
kidney	I:C1561643
disease	I:C1561643
)	O
is	O
high	O
and	O
strategies	O
to	O
reduce	O
this	O
risk	O
are	O
urgently	O
needed	O
.	O

The	O
chronic	B:C1561643
kidney	I:C1561643
disease	I:C1561643
-	O
Medication	O
Intervention	O
Trial	O
(	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
-	O
MIT	O
;	O
www.clinicaltrials.gov;	O
NCTO1459770	I:C4287891
)	O
is	O
a	O
single	O
-	I:C0037181
blind	I:C0037181
(	O
investigators	O
)	O
,	O
randomized	O
,	O
clinical	O
trial	I:C0008976
conducted	O
at	O
Providence	O
Health	I:C0086388
Care	I:C0086388
in	O
Spokane	O
,	I:C3827207
Washington	I:C3827207
.	O

The	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
-	O
Medication	O
Intervention	O
Trial	O
(	O
chronic	B:C1561643
kidney	I:C1561643
disease	I:C1561643
-	O
MIT	O
;	O
www.clinicaltrials.gov;	O
NCTO1459770	I:C4287891
)	O
is	O
a	O
single	O
-	I:C0037181
blind	I:C0037181
(	O
investigators	O
)	O
,	O
randomized	O
,	O
clinical	O
trial	I:C0008976
conducted	O
at	O
Providence	O
Health	I:C0086388
Care	I:C0086388
in	O
Spokane	O
,	I:C3827207
Washington	I:C3827207
.	O

The	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
-	O
Medication	O
Intervention	O
Trial	O
(	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
-	O
MIT	O
;	O
www.clinicaltrials.gov;	B:C4287891
NCTO1459770	I:C4287891
)	O
is	O
a	O
single	O
-	I:C0037181
blind	I:C0037181
(	O
investigators	O
)	O
,	O
randomized	O
,	O
clinical	O
trial	I:C0008976
conducted	O
at	O
Providence	O
Health	I:C0086388
Care	I:C0086388
in	O
Spokane	O
,	I:C3827207
Washington	I:C3827207
.	O

The	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
-	O
Medication	O
Intervention	O
Trial	O
(	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
-	O
MIT	O
;	O
www.clinicaltrials.gov;	O
NCTO1459770	I:C4287891
)	O
is	O
a	O
single	B:C0037181
-	I:C0037181
blind	I:C0037181
(	O
investigators	O
)	O
,	O
randomized	O
,	O
clinical	O
trial	I:C0008976
conducted	O
at	O
Providence	O
Health	I:C0086388
Care	I:C0086388
in	O
Spokane	O
,	I:C3827207
Washington	I:C3827207
.	O

The	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
-	O
Medication	O
Intervention	O
Trial	O
(	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
-	O
MIT	O
;	O
www.clinicaltrials.gov;	O
NCTO1459770	I:C4287891
)	O
is	O
a	O
single	O
-	I:C0037181
blind	I:C0037181
(	O
investigators	B:C0008961
)	O
,	O
randomized	O
,	O
clinical	O
trial	I:C0008976
conducted	O
at	O
Providence	O
Health	I:C0086388
Care	I:C0086388
in	O
Spokane	O
,	I:C3827207
Washington	I:C3827207
.	O

The	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
-	O
Medication	O
Intervention	O
Trial	O
(	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
-	O
MIT	O
;	O
www.clinicaltrials.gov;	O
NCTO1459770	I:C4287891
)	O
is	O
a	O
single	O
-	I:C0037181
blind	I:C0037181
(	O
investigators	O
)	O
,	O
randomized	B:C0034656
,	O
clinical	O
trial	I:C0008976
conducted	O
at	O
Providence	O
Health	I:C0086388
Care	I:C0086388
in	O
Spokane	O
,	I:C3827207
Washington	I:C3827207
.	O

The	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
-	O
Medication	O
Intervention	O
Trial	O
(	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
-	O
MIT	O
;	O
www.clinicaltrials.gov;	O
NCTO1459770	I:C4287891
)	O
is	O
a	O
single	O
-	I:C0037181
blind	I:C0037181
(	O
investigators	O
)	O
,	O
randomized	O
,	O
clinical	B:C0008976
trial	I:C0008976
conducted	O
at	O
Providence	O
Health	I:C0086388
Care	I:C0086388
in	O
Spokane	O
,	I:C3827207
Washington	I:C3827207
.	O

The	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
-	O
Medication	O
Intervention	O
Trial	O
(	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
-	O
MIT	O
;	O
www.clinicaltrials.gov;	O
NCTO1459770	I:C4287891
)	O
is	O
a	O
single	O
-	I:C0037181
blind	I:C0037181
(	O
investigators	O
)	O
,	O
randomized	O
,	O
clinical	O
trial	I:C0008976
conducted	O
at	O
Providence	B:C0086388
Health	I:C0086388
Care	I:C0086388
in	O
Spokane	O
,	I:C3827207
Washington	I:C3827207
.	O

The	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
-	O
Medication	O
Intervention	O
Trial	O
(	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
-	O
MIT	O
;	O
www.clinicaltrials.gov;	O
NCTO1459770	I:C4287891
)	O
is	O
a	O
single	O
-	I:C0037181
blind	I:C0037181
(	O
investigators	O
)	O
,	O
randomized	O
,	O
clinical	O
trial	I:C0008976
conducted	O
at	O
Providence	O
Health	I:C0086388
Care	I:C0086388
in	O
Spokane	B:C3827207
,	I:C3827207
Washington	I:C3827207
.	O

Study	O
participants	O
are	O
hospitalized	O
patients	O
with	O
chronic	B:C1561643
kidney	I:C1561643
disease	I:C1561643
stages	O
3	O
-	O
5	O
(	O
not	O
treated	O
with	I:C0332293
kidney	O
replacement	I:C0206074
therapy	I:C0206074
)	O
and	O
acute	O
illness	O
.	O

Study	O
participants	O
are	O
hospitalized	O
patients	O
with	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
stages	O
3	O
-	O
5	O
(	O
not	O
treated	B:C0332293
with	I:C0332293
kidney	O
replacement	I:C0206074
therapy	I:C0206074
)	O
and	O
acute	O
illness	O
.	O

Study	O
participants	O
are	O
hospitalized	O
patients	O
with	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
stages	O
3	O
-	O
5	O
(	O
not	O
treated	O
with	I:C0332293
kidney	B:C0206074
replacement	I:C0206074
therapy	I:C0206074
)	O
and	O
acute	O
illness	O
.	O

The	O
study	B:C1096775
intervention	I:C1096775
is	O
a	O
pharmacist	O
-	I:C1449564
led	I:C1449564
,	O
home	O
-	I:C0338059
based	I:C0338059
,	O
medication	O
management	I:C0150270
intervention	O
delivered	O
within	O
7	O
days	O
after	O
hospital	O
discharge	I:C0586003
.	O

The	O
study	O
intervention	I:C1096775
is	O
a	O
pharmacist	B:C1449564
-	I:C1449564
led	I:C1449564
,	O
home	O
-	I:C0338059
based	I:C0338059
,	O
medication	O
management	I:C0150270
intervention	O
delivered	O
within	O
7	O
days	O
after	O
hospital	O
discharge	I:C0586003
.	O

The	O
study	O
intervention	I:C1096775
is	O
a	O
pharmacist	O
-	I:C1449564
led	I:C1449564
,	O
home	B:C0338059
-	I:C0338059
based	I:C0338059
,	O
medication	O
management	I:C0150270
intervention	O
delivered	O
within	O
7	O
days	O
after	O
hospital	O
discharge	I:C0586003
.	O

The	O
study	O
intervention	I:C1096775
is	O
a	O
pharmacist	O
-	I:C1449564
led	I:C1449564
,	O
home	O
-	I:C0338059
based	I:C0338059
,	O
medication	B:C0150270
management	I:C0150270
intervention	O
delivered	O
within	O
7	O
days	O
after	O
hospital	O
discharge	I:C0586003
.	O

The	O
study	O
intervention	I:C1096775
is	O
a	O
pharmacist	O
-	I:C1449564
led	I:C1449564
,	O
home	O
-	I:C0338059
based	I:C0338059
,	O
medication	O
management	I:C0150270
intervention	B:C0184661
delivered	O
within	O
7	O
days	O
after	O
hospital	O
discharge	I:C0586003
.	O

The	O
study	O
intervention	I:C1096775
is	O
a	O
pharmacist	O
-	I:C1449564
led	I:C1449564
,	O
home	O
-	I:C0338059
based	I:C0338059
,	O
medication	O
management	I:C0150270
intervention	O
delivered	O
within	O
7	O
days	O
after	O
hospital	B:C0586003
discharge	I:C0586003
.	O

The	O
primary	O
outcome	O
is	O
a	O
composite	O
of	O
hospital	B:C0600290
readmissions	I:C0600290
and	O
visits	O
to	O
emergency	O
departments	I:C0562508
and	O
urgent	O
care	I:C1710587
centers	I:C1710587
for	O
90	O
days	O
following	O
hospital	O
discharge	I:C0586003
.	O

The	O
primary	O
outcome	O
is	O
a	O
composite	O
of	O
hospital	O
readmissions	I:C0600290
and	O
visits	O
to	O
emergency	B:C0562508
departments	I:C0562508
and	O
urgent	O
care	I:C1710587
centers	I:C1710587
for	O
90	O
days	O
following	O
hospital	O
discharge	I:C0586003
.	O

The	O
primary	O
outcome	O
is	O
a	O
composite	O
of	O
hospital	O
readmissions	I:C0600290
and	O
visits	O
to	O
emergency	O
departments	I:C0562508
and	O
urgent	B:C1710587
care	I:C1710587
centers	I:C1710587
for	O
90	O
days	O
following	O
hospital	O
discharge	I:C0586003
.	O

The	O
primary	O
outcome	O
is	O
a	O
composite	O
of	O
hospital	O
readmissions	I:C0600290
and	O
visits	O
to	O
emergency	O
departments	I:C0562508
and	O
urgent	O
care	I:C1710587
centers	I:C1710587
for	O
90	O
days	O
following	O
hospital	B:C0586003
discharge	I:C0586003
.	O

Secondary	O
outcomes	O
are	O
achievements	O
of	O
guideline	B:C0162791
-	I:C0162791
based	I:C0162791
targets	O
for	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
risk	O
factors	I:C0035648
and	O
complications	O
.	O

Secondary	O
outcomes	O
are	O
achievements	O
of	O
guideline	O
-	I:C0162791
based	I:C0162791
targets	O
for	O
chronic	B:C1561643
kidney	I:C1561643
disease	I:C1561643
risk	O
factors	I:C0035648
and	O
complications	O
.	O

Secondary	O
outcomes	O
are	O
achievements	O
of	O
guideline	O
-	I:C0162791
based	I:C0162791
targets	O
for	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
risk	B:C0035648
factors	I:C0035648
and	O
complications	O
.	O

Secondary	O
outcomes	O
are	O
achievements	O
of	O
guideline	O
-	I:C0162791
based	I:C0162791
targets	O
for	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
risk	O
factors	I:C0035648
and	O
complications	B:C0009566
.	O

Enrollment	B:C1516879
began	O
in	O
February	O
2012	O
and	O
ended	O
in	O
May	O
2015	O
.	O

At	O
baseline	O
,	O
the	O
age	O
of	O
participants	B:C0679646
was	O
69	O
±	O
11	O
years	O
(	O
mean	O
±	O
SD	O
)	O
,	O
50	O
%	O
(	O
77	O
of	O
155	O
)	O
were	O
women	O
,	O
83	O
%	O
(	O
117	O
of	O
141	O
)	O
had	O
hypertension	O
and	O
56	O
%	O
(	O
79	O
of	O
141	O
)	O
had	O
diabetes	O
.	O

At	O
baseline	O
,	O
the	O
age	O
of	O
participants	O
was	O
69	O
±	O
11	O
years	O
(	O
mean	O
±	O
SD	O
)	O
,	O
50	O
%	O
(	O
77	O
of	O
155	O
)	O
were	O
women	B:C0043210
,	O
83	O
%	O
(	O
117	O
of	O
141	O
)	O
had	O
hypertension	O
and	O
56	O
%	O
(	O
79	O
of	O
141	O
)	O
had	O
diabetes	O
.	O

At	O
baseline	O
,	O
the	O
age	O
of	O
participants	O
was	O
69	O
±	O
11	O
years	O
(	O
mean	O
±	O
SD	O
)	O
,	O
50	O
%	O
(	O
77	O
of	O
155	O
)	O
were	O
women	O
,	O
83	O
%	O
(	O
117	O
of	O
141	O
)	O
had	O
hypertension	B:C0020538
and	O
56	O
%	O
(	O
79	O
of	O
141	O
)	O
had	O
diabetes	O
.	O

At	O
baseline	O
,	O
the	O
age	O
of	O
participants	O
was	O
69	O
±	O
11	O
years	O
(	O
mean	O
±	O
SD	O
)	O
,	O
50	O
%	O
(	O
77	O
of	O
155	O
)	O
were	O
women	O
,	O
83	O
%	O
(	O
117	O
of	O
141	O
)	O
had	O
hypertension	O
and	O
56	O
%	O
(	O
79	O
of	O
141	O
)	O
had	O
diabetes	B:C0011847
.	O

At	O
baseline	O
,	O
the	O
estimated	B:C3811844
glomerular	I:C3811844
filtration	I:C3811844
rate	O
was	O
41	O
±	O
14	O
ml	O
/	O
min/1.73	O
m2	O
and	O
urine	O
albumin	I:C0455271
-	I:C0455271
to	I:C0455271
-	I:C0455271
creatinine	I:C0455271
ratio	I:C0455271
was	O
43	O
mg/g	O
(	O
interquartile	O
range	O
8	O
-528	O
mg	O
/	O
g	O
)	O
.	O

At	O
baseline	O
,	O
the	O
estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	O
was	O
41	O
±	O
14	O
ml	O
/	O
min/1.73	O
m2	O
and	O
urine	B:C0455271
albumin	I:C0455271
-	I:C0455271
to	I:C0455271
-	I:C0455271
creatinine	I:C0455271
ratio	I:C0455271
was	O
43	O
mg/g	O
(	O
interquartile	O
range	O
8	O
-528	O
mg	O
/	O
g	O
)	O
.	O

The	O
most	O
frequent	O
diagnosis	O
category	O
for	O
the	O
index	O
hospital	B:C0184666
admission	I:C0184666
was	O
cardiovascular	O
diseases	I:C0007222
at	O
34	O
%	O
(	O
53	O
of	O
155	O
)	O
,	O
but	O
the	O
most	O
common	O
single	O
diagnosis	I:C0011900
for	O
admission	O
was	O
community	O
-	O
acquired	O
acute	O
kidney	I:C0022660
injury	I:C0022660
at	O
10	O
%	O
(	O
16	O
of	O
155	O
)	O
.	O

The	O
most	O
frequent	O
diagnosis	O
category	O
for	O
the	O
index	O
hospital	O
admission	I:C0184666
was	O
cardiovascular	B:C0007222
diseases	I:C0007222
at	O
34	O
%	O
(	O
53	O
of	O
155	O
)	O
,	O
but	O
the	O
most	O
common	O
single	O
diagnosis	I:C0011900
for	O
admission	O
was	O
community	O
-	O
acquired	O
acute	O
kidney	I:C0022660
injury	I:C0022660
at	O
10	O
%	O
(	O
16	O
of	O
155	O
)	O
.	O

The	O
most	O
frequent	O
diagnosis	O
category	O
for	O
the	O
index	O
hospital	O
admission	I:C0184666
was	O
cardiovascular	O
diseases	I:C0007222
at	O
34	O
%	O
(	O
53	O
of	O
155	O
)	O
,	O
but	O
the	O
most	O
common	O
single	B:C0011900
diagnosis	I:C0011900
for	O
admission	O
was	O
community	O
-	O
acquired	O
acute	O
kidney	I:C0022660
injury	I:C0022660
at	O
10	O
%	O
(	O
16	O
of	O
155	O
)	O
.	O

The	O
most	O
frequent	O
diagnosis	O
category	O
for	O
the	O
index	O
hospital	O
admission	I:C0184666
was	O
cardiovascular	O
diseases	I:C0007222
at	O
34	O
%	O
(	O
53	O
of	O
155	O
)	O
,	O
but	O
the	O
most	O
common	O
single	O
diagnosis	I:C0011900
for	O
admission	B:C0030673
was	O
community	O
-	O
acquired	O
acute	O
kidney	I:C0022660
injury	I:C0022660
at	O
10	O
%	O
(	O
16	O
of	O
155	O
)	O
.	O

The	O
most	O
frequent	O
diagnosis	O
category	O
for	O
the	O
index	O
hospital	O
admission	I:C0184666
was	O
cardiovascular	O
diseases	I:C0007222
at	O
34	O
%	O
(	O
53	O
of	O
155	O
)	O
,	O
but	O
the	O
most	O
common	O
single	O
diagnosis	I:C0011900
for	O
admission	O
was	O
community	O
-	O
acquired	O
acute	B:C0022660
kidney	I:C0022660
injury	I:C0022660
at	O
10	O
%	O
(	O
16	O
of	O
155	O
)	O
.	O

Participants	B:C0679646
in	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
-	O
MIT	O
are	O
typical	O
of	O
acutely	O
ill	O
hospitalized	O
patients	O
with	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
.	O

Participants	O
in	O
chronic	B:C1561643
kidney	I:C1561643
disease	I:C1561643
-	O
MIT	O
are	O
typical	O
of	O
acutely	O
ill	O
hospitalized	O
patients	O
with	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
.	O

Participants	O
in	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
-	O
MIT	O
are	O
typical	O
of	O
acutely	O
ill	O
hospitalized	O
patients	O
with	O
chronic	B:C1561643
kidney	I:C1561643
disease	I:C1561643
.	O

A	O
medication	B:C0150270
management	I:C0150270
intervention	O
after	O
hospital	O
discharge	I:C0586003
is	O
under	O
study	O
to	O
reduce	O
post	O
-	O
hospitalization	O
acute	O
care	I:C0679878
utilization	O
and	O
to	O
improve	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
management	O
.	O

A	O
medication	O
management	I:C0150270
intervention	B:C0184661
after	O
hospital	O
discharge	I:C0586003
is	O
under	O
study	O
to	O
reduce	O
post	O
-	O
hospitalization	O
acute	O
care	I:C0679878
utilization	O
and	O
to	O
improve	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
management	O
.	O

A	O
medication	O
management	I:C0150270
intervention	O
after	O
hospital	B:C0586003
discharge	I:C0586003
is	O
under	O
study	O
to	O
reduce	O
post	O
-	O
hospitalization	O
acute	O
care	I:C0679878
utilization	O
and	O
to	O
improve	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
management	O
.	O

A	O
medication	O
management	I:C0150270
intervention	O
after	O
hospital	O
discharge	I:C0586003
is	O
under	O
study	B:C2603343
to	O
reduce	O
post	O
-	O
hospitalization	O
acute	O
care	I:C0679878
utilization	O
and	O
to	O
improve	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
management	O
.	O

A	O
medication	O
management	I:C0150270
intervention	O
after	O
hospital	O
discharge	I:C0586003
is	O
under	O
study	O
to	O
reduce	O
post	O
-	O
hospitalization	B:C0019993
acute	O
care	I:C0679878
utilization	O
and	O
to	O
improve	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
management	O
.	O

A	O
medication	O
management	I:C0150270
intervention	O
after	O
hospital	O
discharge	I:C0586003
is	O
under	O
study	O
to	O
reduce	O
post	O
-	O
hospitalization	O
acute	B:C0679878
care	I:C0679878
utilization	O
and	O
to	O
improve	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
management	O
.	O

A	O
medication	O
management	I:C0150270
intervention	O
after	O
hospital	O
discharge	I:C0586003
is	O
under	O
study	O
to	O
reduce	O
post	O
-	O
hospitalization	O
acute	O
care	I:C0679878
utilization	O
and	O
to	O
improve	O
chronic	B:C1561643
kidney	I:C1561643
disease	I:C1561643
management	O
.	O

A	O
medication	O
management	I:C0150270
intervention	O
after	O
hospital	O
discharge	I:C0586003
is	O
under	O
study	O
to	O
reduce	O
post	O
-	O
hospitalization	O
acute	O
care	I:C0679878
utilization	O
and	O
to	O
improve	O
chronic	O
kidney	I:C1561643
disease	I:C1561643
management	B:C0376636
.	O

